StockData
OKURNasdaqPharmaceutical PreparationsFiscal year ends December 31

OnKure Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$2.25+0.15 (+7.14%)

Close on Oct 19, 2026

Market cap
$112.21M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 4, 2026After market close–$-0.31–
Q1 FY2026
Ended Mar 31, 2026
May 5, 2026After market close–––
Q4 FY2025
Ended Dec 31, 2025
Mar 12, 2026After market close–$-0.99–
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025After market close–$-1.09–
Q2 FY2025
Ended Jun 30, 2025
Aug 12, 2025After market close–$-1.14–
Q1 FY2025
Ended Mar 31, 2025
May 6, 2025Before market open–$-1.19–
Q4 FY2024
Ended Dec 31, 2024
Mar 10, 2025After market close–$-1.37–
Q2 FY2024
Ended Jun 30, 2024
Aug 13, 2024After market close–––
Q1 FY2024
Ended Mar 31, 2024
May 7, 2024After market close–$-0.25–
Q4 FY2023
Ended Dec 31, 2023
Mar 28, 2024After market close–$-0.70–
Q3 FY2023
Ended Sep 30, 2023
Nov 13, 2023After market close–$-0.57–

Press releases

Announcements OnKure Therapeutics filed with the SEC